Clinical Trial Update: Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pioglitazone in combination with a tyrosine kinase inhibitor for relapsed chronic myeloid leukemia (BCR-ABL1 positive); study termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia Bcr-abl1-positive

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: Emory University | Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Status: TERMINATED | Results posted: 2019-01-09